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ABSTRACT 
Himes, Evan R. M.S., Purdue University, August 2013. The Role of STAT3 in Osteoclast 
Mediated Bone Resorption. Major Professor: Jiliang Li. 
 
 
Signal Transducer and Activator of Transcription 3 (STAT3) is known to be 
related to bone metabolism.  Mutation of STAT3 causes a rare disorder in which serum 
levels of IgE are elevated.  This causes various skeletal problems similar to osteoporosis. 
To examine the effect of STAT3 in the osteoclast, we obtained two osteoclast 
specific STAT3 knockout mouse models: one using the CTSK promoter to drive Cre 
recombinase and another using a TRAP promoter.  Examination of these mice at 8 weeks 
of age revealed a decreased trabecular bone volume in CTSK specific STAT3 knockout 
mice along with a slight decrease in osteoclast number in both CTSK and TRAP specific 
STAT3 knockout females.  We also noticed changes in bone mineral density and bone 
mechanical strength in females.  These data suggest that STAT3 plays a part in the 
function of the osteoclast.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Skeletal Structure 
 
The skeleton of the adult human is made up of 206 bones carrying out various 
tasks, such as providing a framework to move and support the body, protection of vital 
organs, and playing a part in mineral homeostasis.  Bones may be divided into several 
groups, including long bones such as those found in the limbs (femur, humerus) and flat 
bones such as the bones of the skull.  The long bones are further divided into the 
epiphysis, metaphysis, and diaphysis.  The diaphysis is a long and hollowed out shaft that 
spans most of the bone.  The metaphysis is the portion of bone between the diaphysis and 
the growth plate, while the epiphysis is the region beyond the growth plate  at each end of 
the bone [1]. 
 
1.2 Bone Macroscopic Anatomy 
 
The inner and outer surfaces of bone are covered in fibrous sheaths.  The outer 
surface is covered in the periosteum, with the exception of areas where joints are located.  
The periosteum is anchored to the underlying bone by collagenous fibers called 
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Sharpey’s fibers.  The periosteum contains the blood vessels and nerves running to the 
bone, along with osteoblasts and osteoclasts, two cells responsible for building up and 
breaking down of bone tissue, respectfully. 
The endosteum covers the inner surface of the bone and similar to the periosteum, 
the endosteum also contains blood vessels, nerves, osteoblasts, and osteoclasts.  
Volkman’s canals and Haversian canals which contain blood vessels run through the 
bone [1]. 
 All bone is arranged in two different formats, cortical bone and cancellous or 
trabecular bone.  Overall, the human skeleton contains more cortical bone than trabecular 
bone, but this can vary between different locations of the skeleton.  Cortical bone appears 
to be very dense while trabecular bone appears to be a network of rods running between 
the cortical bone.  Both cortical and trabecular bone is made up of the same basic 
functional unit: the osteon.  Osteons are arranged into Haversian systems in cortical bone 
and saucers in trabecular bone. (Figure 1)  The Haversian systems form cylinders running 
the length of cortical bone and are made of concentric circles of lamellae. In trabecular 
bone, the lamellae are stacked together to form saucer-shaped osteons. [1]  
 The extracellular matrix of bone is composed of a protein network and a mineral 
component.  The organic protein component gives the bone elasticity, while the mineral 
gives the bone strength.  The majority of the protein in bone is type 1 collagen, which is 
made from two α1 chains and one α2 chain. [2]  Smaller amounts of type III and V 
collagens are also present. [3]  The remaining 10-15% of the protein component is made 
of non-collagenous proteins.  About ¼ of these are exogenously made serum proteins that 
have an affinity for hydroxyapatite. [4]  The remaining non-collagenous proteins are 
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broken into four groups:  proteoglycans, glycosylated proteins, glycosylated proteins with 
cell attachment properties, and γ-carboxylated proteins.  The mineral component makes 
up between 50-70% of bone in an adult and is composed of hydroxyapatite, 
[Ca10(PO4)6(OH)2].  This mineral is initially deposited in sites left open by the collagen 
fibrils.  These crystals become larger as the bone matures and aggregate as they increase 
in size. [5-7]   
 
1.3 Bone Modeling 
 
Bone structure can be changed through two different processes: modeling and 
remodeling.  In bone modeling, the osteoblasts or osteoclasts shape the bone through 
either resorption or formation.  As an example, the continuous use of an arm can change 
the size of the radius in tennis athletes. [8]  Bone modeling is more common among 
children who are still growing than in adults.  In remodeling, bone resorption and 
formation are coupled.  This involves the breakdown of bone by osteoclasts immediately 
followed by new bone formation by osteoblasts. [1] 
 
1.4 Bone Remodeling 
 
Remodeling is broken down into 4 phases: activation, resorption, reversal, and formation.  
The cells involved in this process arrange themselves in a bone remodeling unit, or BRU 
(Figure 2). [9]  During activation, mononucleated osteoclast precursors are recruited and 
fused into multinucleated cells.  These preosteoclasts attach to the bone via integrins, 
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forming a sealed environment within which they can degrade the bone matrix. [10]  
Destruction of the bone matrix by the osteoclasts begins after activation and is explained 
below.  Reversal begins after the death of the osteoclasts.  The bone is covered by a 
variety of cells during this phase, including monocytes, exposed osteocytes, and 
preosteoblasts. [1]  
 During formation, osteoblasts first synthesize a protein matrix and then regulate 
mineral deposition through secretion of membrane vesicles. These vesicles contain 
calcium and phosphate ions and enzymes to degrade inhibitors of mineralization.[11]  
After bone formation the osteoblasts can become osteocytes as they are trapped within 
the bone or bone lining cells.  However, the majority of osteoblasts undergo apoptosis at 
the end of bone formation. [1]  Bone remodeling differs from modeling in that resorption 
and formation occur on the same bone surface during remodeling. 
 
1.5 Bone Cells 
 
Bone is comprised of three cell types:  osteoblasts, osteocytes, and osteoclasts.  
The osteoblasts are responsible for building the bone matrix, while osteoclasts are 
responsible for breaking down bone matrix.  Osteocytes are thought to be involved in 
signaling processes.  Both osteoblasts and osteocytes come from the mesenchymal stem 
cell lineage, while the osteoclasts arise from hematopoietic stem cells. [12]   
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The commitment of mesenchymal stem cells to become osteoblasts is mediated 
by multiple factors, including Runx2, osterix, and Dlx5. [13]  Bone morphogenic proteins 
are also inducers of osteoblast formation.  These are members of the TGF-β superfamily 
and include BMP-2, BMP-4, and BMP-7. [14]  
 Osteocytes are the final stage of differentiation for osteoblasts.  Osteocytes are 
located within lacunae in the bone matrix and have long extensions into the canaliculi, 
through which they communicate.  Osteocytes produce large amounts of osteocalcin, 
galectin-3, and CD44. [14]   
 
1.6 The Osteoclast 
 
The osteoclast is responsible for bone resorption and, unlike osteoblasts and 
osteocytes, come from the monocyte/macrophage lineage. [15]  Osteoclasts are 
developed in vitro with the addition of receptor activator of nuclear factor kappa-B ligand 
(RANKL) and macrophage colony-stimulating factor (M-CSF). [16, 17]  Both proteins 
are produced by osteoblasts. 
 Osteoclasts resorb bone through the formation of a sealed environment between 
the cell and the underlying bone.  This is accomplished using integrins, which are 
transmembrane receptors made of one α and one β subunit. [18]  Specifically, the αvβ3 
integrin is responsible for osteoclast-bone attachment.  The αvβ3 binds to RGD motifs, 
found on various bone related protein, including bone sialoprotein and osteopontin.  The 
αvβ3 integrin was discovered to be necessary for osteoclast attachment in a study using a 
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β3 integrin knock out mouse, which led to an increase in bone mass. [19]  Inhibition of 
osteoclast binding through αvβ3 is a target under study for treatment of osteoporosis. [20] 
 The osteoclast requires a specialized cytoskeleton to function correctly.  Binding 
to bone causes the osteoclast cytoskeleton to form two unique structures: the ruffled 
membrane and the sealing zone.  The ruffled membrane gets its name from the shape 
created by the vesicles carrying cathepsin K, a lysosomal enzyme secreted by the 
osteoclast, and matrix metalloproteinases (MMPs) to the cell surface. [21]  This area also 
houses proton pumps and a chloride ion channel used to bring the pH of this 
microenvironment to approximately 4.5 which dissolves bone’s mineral component, 
leaving the organic component behind. [22]  The organic matrix is primarily type 1 
collagen, which is broken down by enzymes such as cathepsin K and tartrate-resistant 
acid phosphatase.  The sealing zone is made from fibrillar actin and serves to separate the 
area being resorbed by the osteoclast from the surrounding environment. [23]   
Osteoclast rearrangement is mediated through integrin signaling and the Rho 
family of small GTPases.  Integrin signaling through the adaptor protein c-Src stimulates 
formation of the ruffled membrane [24].  Both Rho and Rac translocate to the 
cytoskeleton after binding GTP.  Rho signalling leads to formation of the actin ring, [25, 
26]  while Rac signaling stimulates the formation of lamellipodia, which allows the 
osteoclast to migrate. [27]   
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1.7 Enzymes Involved in Bone Resorption 
 
1.7.1 Cathepsin K (CTSK) 
 
CTSK is an enzyme responsible for breaking down the organic matrix of bone.  
CTSK is primarily expressed by the osteoclast, with some expression occurring in the 
lung. [28]  The gene for CTSK is found on chromosome 1 and transcription of CTSK is 
activated by RANKL and M-CSF.  Transforming growth factor β1 (TGFβ1) and 
interleukin 10 (IL-10) both inhibit CTSK, which has a molecular mass of 24 kDa and 
consists of two domains, forming a v-shaped active site. [29]   
 
1.7.2 Tartrate Resistant Acid Phosphatase (TRAP) 
 
TRAP is a 35kDa metalloenzyme that breaks down phosphate esters or 
anhydrides. [30]  While TRAP is primarily expressed in bone, it can also be found in the 
colon, kidney, liver, and testes. [28]  TRAP has a molecular weight of about 35 kDa.  
Osteoclasts are commonly identified by staining for cells expressing TRAP. 
 
1.8 Osteoclast Regulation 
 
RANKL and M-CSF are the most well-known activators of osteoclastogenesis.  
RANKL is inhibited by Osteoprotegrin (OPG), a competitive inhibitor of RANKL.  Both 
RANKL and OPG are produced by the osteoblast. [31]  Interferon-γ (IFN-γ) also 
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suppresses osteoclast function [32] and  vitamin D  increases RANKL concentration 
while decreasing Osteoprotegrin levels, causing an increase in bone volume. [31]   
The hormone estrogen prevents bone resorption and loss of estrogen in the aging 
process has been shown to contribute to bone loss. [33]  Estrogen upregulates osteoblast 
formation through bone morphogenic protein 4 (BMP-4). [34]  Glucocortocoids act as 
negative osteoclast regulators by increasing osteoblast apoptosis which leads to a 
decrease in RANKL. [35]   
 
1.9 Bone Biomechanics 
 
Bone can be strengthened in two ways: through the addition of more bone to help 
carry a load or through improving the bone’s material composition.  Bone strength can be 
quantified by various measurements, such as strain and stress.  Strain is the change in 
length of an object divided by its original length and therefore has no unit.  A strain can 
be tensile if the material is being stretched or compressive if the material is being pushed 
together.  Shear stress is the angle of deformation by a force that is running parallel to the 
material, and is generated in bone during rapid changes in direction.  Stress is a measure 
of force per unit area. [36] 
 Modulus is another measure of strength and is the slope of the initial linear part of 
the stress vs. strain curve (Figure 3).  This is also referred to as the elastic part of the 
curve since the removal of force allows the object being tested to return to its original 
state undamaged.  The linear relationship of the stress-strain curve is also referred to as 
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Hooke’s Law. The slope of the stress-strain curve in the elastic region is a measure of a 
material’s stiffness.  A larger slope of the stress-strain curve equals a higher stiffness. [36] 
 Two points of failure are observed when testing the strength of a material: yield 
failure and ultimate failure.  Yield failure is the point where stress and strain do not have 
a linear relationship and is the point where permanent damage occurs.  The region 
beyond this point on the stress-strain curve is referred to as the plastic region.  Ultimate 
failure is the point at which the material being tested fails catastrophically. Toughness is 
a measure of a material’s ability to resist fracture when put under a sudden load. [36]  
 
1.10 Hyper-IgE Syndrome 
 
Hyperimmunoglobulin E syndrome (HIES), also known as Job’s syndrome, was 
originally discovered in 1966 by Davis et al.  They described symptoms as a recurrent 
‘cold’ and staphylococcal abscess. [37]  HIES was and named in 1972 by Buckley at al. 
and characterized as having an increase in IgE concentration of up to 10 times the normal 
serum levels. [38] 
HIES results in various infections and skeletal abnormalities as well as dental 
problems, including retained primary teeth and also failure of permanent teeth to erupt or 
permanent tooth eruption next to primary teeth, resulting in two rows of teeth.  Eczema, 
skin abscesses, pneumonia, and candidiasis of the nail bed and mucus membranes are 
common.  HIES patients also have an increased risk of bone fracture as shown in 1999 by 
Grimbacher et al. [39]  Most fractures in the 30 patient study were a result of everyday 
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tasks, including diaper changing and line dancing The majority of these fractures were in 
long weight-bearing bones such as the femur along with the ribs and pelvis. 
When fractures do occur, bacterial arthritis and osteomyelitis can be found.  The 
study also found that scoliosis occurred in 76% of HIES patients.  HIES can result in 
hyperextensible joints and a distinctive facial appearance, including an asymmetrical 
face, deep-set eyes, a broad nose, and a prominent forehead. [39, 40]  
HIES is caused by one of two genetic mutations, autosomal-recessive HIES and 
autosomal-dominant HIES. [41]  Both have been linked to chromosome 4. [42]  A 2007 
study by Holland et al. determined mutations of STAT3 was the cause of HIES. [43]  All 
mutations were in either the DNA binding region or SH2 domain of STAT3. 
 
1.11 Signal Transducers and Activators of Transcription 
 
STAT3 is one of a family of 7 STAT proteins which includes Stat1, Stat2, Stat3, 
Stat4, Stat5a, Stat5b, and Stat6.  The Stat proteins are part of the Janus kinase (JAK)-
STAT signaling pathway.  The JAK family of proteins includes JAK1, JAK2, JAK3, and 
Tyk2. [44]  This pathway was originally discovered while looking at the actions of 
interferons.  The STAT genes are located on multiple chromosomes:  STAT1 and STAT4 
are on chromosome 2, STAT3 STAT5a and STAT5b are located on chromosome 12, and 
STAT2 and STAT6 are on chromosome 17.  All STATs are activated by phosphorylation 
of a tyrosine residue located around position 700.  The STATs range in size between 750 
and 850 amino acids long. [45]  
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1.12 JAK-STAT Pathway 
 
The JAK-STAT pathway can be activated in many ways.  Activation occurs with 
the binding of one of the interlukin-6 (IL-6) type cytokines to their receptors.  This family 
of cytokines is also referred to as the gp130 family and consists of IL-6, IL-11, oncostatin 
M, leukemia inhibitory factor, cardiotrophin-1, and the novel neurotrophin-1/B-cell 
stimulatory factor-3. [46, 47]  When these cytokines bind their respective receptors gp130 
dimerizes, therefore activating JAK.  Once JAK is activated it phosphorylates a tyrosine 
in a YXXQ motif of the receptor’s cytoplasmic tail.  The phosphorylated receptor then 
attracts the SH2 domain of a STAT, which then becomes phosphorylated at a tyrosine.  
This leads to the dimerization of the STAT and the movement of the dimerized STAT to 
the nucleus, where it can bind DNA and act as a transcription activator. [48]  The JAK-
STAT pathway can also be activated by STAT phosphorylation by epidermal growth 
factor (EGF) or platelet-derived growth factor (PDGF).  In addition, JAKs may be 
activated by G-protein –coupled receptors (Figure 4). [49]   
 
1.13 STAT3 Structure 
 
STAT3 contains multiple domains, each with a different function.  The N-domain, 
coiled-coil domain, linker domain, DNA binding domain, SH2 domain, and carboxy 
terminal transcriptional activation domain all make up the STAT3 protein. [50] (Figure 5) 
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 The amino-terminal domain of STAT3 is involved in regulation.  Two STAT3 
dimers can bind to form a tetramer that helps form a more stable DNA binding complex.  
The amino-terminal domain may also be a drug target for anticancer drugs. [51, 52]  The 
coiled-coil domain is a hydrophilic region made of four antiparallel α helices and is 
necessary for STAT3 to translocate to the nucleus. [53, 54]  The coiled-coil region can 
also be used to bind the C-terminus of the interleukin-22 receptor to activate STAT3.  
Normally, STAT3 is activated by the association of the SH2 domain with a 
phosphorylated tyrosine on a cytokine receptor. [55]  The coiled-coil region has also been 
found to be required for the STAT3 SH2 domain to bind a cytokine receptor through 
studies involving the deletion of α helixes 1 and 2. [56]   
 The DNA binding domain appears similar to an immunoglobulin, with two long β 
strands running perpendicular to the DNA.  This domain consists of amino acids 320 to 
480 and binds to interferon gamma activated sequences (GAS). [50] 
The SH2 domain consists of two α helices surrounding an antiparallel β sheet. [53, 
54]  This region of STAT3 is responsible for both binding to receptors and dimer 
formation.  The specificity of this region determines the differences in activation between 
members of the STAT protein family. [57]   
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1.14 STAT3 Activation 
 
STAT3 can be activated in a number of ways.  The primary method of activation is 
through the binding of IL-6 type cytokines to the extracellular part of their receptors to 
start the JAK-STAT pathway.  Cytokines in this family include IL-6, IL-11, oncostatin M 
(OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), and 
cardiotrophin-1 (CT-1).  These cytokines are all similar in size and shape.  The majority 
of IL-6 type cytokine receptors are transmembrane proteins with an extracellular amino 
end and one transmembrane domain.  The one exception is the ciliary neurotrophic factor 
receptor, which uses a lipid anchored protein receptor.  After ligand binding, the 
receptors dimerize.  All cytokine signals use at least one gp130 as a receptor.  IL-6 
signaling uses two gp130s while all other cytokines use one gp130 and one leukemia 
inhibitory factor receptor.  Oncostatin M uses one gp130 and one oncostatin M receptor. 
[46]  All of these receptor subunits are capable of activating JAKs and recruiting STAT3.  
IL-6, IL-11, and CNTF all have their own α receptor subunits that are involved in the 
recruitment of the other two receptor subunits. (Figure 6)  Dimerization of the two 
cytokine receptor subunits leads to activation of a janus kinase (JAK).  The JAK trans-
phosphorylates the cytoplasmic side of the receptor, which leads to recruitment of 
STAT3.  JAKs phosphorylate a tyrosine residue of the YXXQ motif on the receptor. 
STAT3 can also be activated by the receptors for epidermal growth factor (EGF), 
platelet derived growth factor (PDGF), or fibroblast growth factor (FGF), which are 
members of different receptor tyrosine kinases.  These can phosphorylate STAT3 directly 
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without the use of a Janus kinase.  Another method of activation for this pathway is the 
activation of Janus kinase through G-protein-coupled receptors. [58]   
 
1.15 STAT3 Localization 
 
The STAT proteins vary by the method in which they can enter the nucleus. [59]  
For example, STAT1 and STAT2 must be phosphorylated to enter the nucleus but 
STAT3 does not.  An 11 amino acid long nuclear-localization signal of the coiled-coil 
domain is all that is required for STAT3 to enter the nucleus. [60]  However, STAT3 
must still be phosphorylated to bind DNA.  The import of STAT3 to the nucleus is 
mediated by importin-α3, which binds to the nuclear-localization signal. [59]   
1.16 Regulators of STAT3 
 
There are various suppressors of STAT3 signalling.  One group of proteins known 
to suppress all STATs is the suppressors of cytokine signaling (SOCS).  SOCS can 
inhibit STAT3 signaling by interacting with the cytokine receptors, inhibiting JAKs, 
inhibiting the binding of STATs, and marking STATs for degradation by proteasomes. 
[61]  SOCS were discovered by multiple groups, so they are also be referred to as JAK-
binding protein (JAB) or STAT-induced STAT inhibitor (SSI). [58]  Additionally, 
cytokine-inducible SH2-containing protein (CIS) is also a negative regulator of STAT3. 
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 Inhibition and inactivation of STAT3 is carried out by protein inhibitor of 
activated STAT (PIAS).  The family of PIAS includes PIAS1, PIAS3, PIASy, 
PIASxα/ARIP3, and PIASxβ /Miz1.  PIAS3 is regulates STAT3 by binding 
phosphporylated STAT3 and preventing DNA binding. [62]  Cyclin D1 is also an 
important negative regulator of STAT3 and is overexpressed in various forms of cancer. 
[63, 64]   
 
1.17 STAT3 Knockout Mouse Model 
 
The knockout of STAT3 is lethal at the embryonic stage and STAT3 knockout 
mouse embryos usually do not survive beyond 7.5 days.  STAT3 is the only member of 
the STAT protein family in which knockout leads to death of the animal.  Therefore, to 
study STAT3, a conditional knockout model is necessary.  This is accomplished using the 
Cre-loxp recombination system. 
 
1.18 STAT3 in Bone 
 
STAT3 is known to play a major role in bone homeostasis.  Osteoblast-specific 
STAT3 knockout mice are decreased in size and bone density.  These mice also display 
decreased bone mineral density and bone area.  Bone growth rate and strength are 
decreased. [65]  The osteoblast-specific STAT3 knockout also shows a decrease in load-
driven bone formation and an increase in reactive oxygen species (ROS) levels, 
indicating decreased mitochondrial activity. [65]   
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 In vitro studies revealed that inhibition of JAK2 with AG490 causes decreased 
osteoclastogenesis.  An osteoclast precursor cell line treated with AG490 resulted in 
decreased cell proliferation, regardless of how much RANKL was added.  This 
demonstrated that the JAK2/STAT3 pathway is involved in RANKL mediated 
osteoclastogenesis.   [66]  
 
1.19 Research Goals 
 
We hypothesize that the loss of STAT3 in osteoclasts will lead to decreased 
osteoclast proliferation and therefore an increase in bone size and strength.  To test this, 
we acquired two osteoclast-specific STAT3 knockout mouse models and observed bone 
mineral density, bone structure, strength, and conducted histomorphometrical analysis of 
the mouse’s femur at 8 and 16 weeks.  Osteoclasts were also isolated to determine their 
activity levels. 
 
 
 
 
 
 
 
 
17 
 
1
7
 
 
 
 
CHAPTER 2. MATERIALS AND METHOD 
 
2.1 Conditional STAT3 Knockout Mice 
 
Osteoclast-specific mice were generated using the Cre-loxP system.  Floxed 
STAT3 mice were bred with mice expressing Cre recombinase.  In this experiment, two 
mouse strains were used: one in which Cre is driven by the promoter for cathepsin K 
(CTSK) and another driven by the tartrate-resistant acid phosphatase (TRAP) promoter.  
The Stat3 floxed mice were obtained from Dr.Xin-Yuan Fu in the Department of 
Microbiology and Immunology, Indiana University School of Medicine.  Both the 
CTSK- Cre and TRAP-Cre mice came from the University of Melbourne, Australia.  The 
STAT3 floxed mice contain two loxp sequences flanking exons 18-20 of the STAT3 gene.  
Mice that were homozygous for the loxP sites (STAT3
flox/flox
) and the Cre transgene 
(CTSK-cre or TRAP-cre) were used as conditional knockout mice.  Mice that were wild-
type for the loxP site (STAT3
+/+
) and homozygous for the Cre transgene were used for 
control.  All procedures were performed in accordance with guidelines provided by the 
IACUC. 
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2.2 PCR for STAT3 and Cre Genes 
 
Mouse genotype was confirmed through polymerase chain reaction (PCR).  
Approximately 2mm was cut from the tip of the tail of each mouse and stored in a 1.5mL 
microcentrifuge tube.  Scissors were sterilized between mice using 70% ethanol.  A lysis 
buffer was prepared with 50mM Tris, 50mM KCl, 2.5mM EDTA, 0.4% NP-40, and 0.45% 
Tween-40.  0.4mg/mL proteinase K was added immediately before use.  100µL of the 
lysis buffer was added to each tube.  The tubes with tail samples were placed in a 56°C 
water bath overnight.  The next day the tubes were transferred to a 95°C dry bath for 10 
min.  The tail samples were then diluted with 100µL autoclaved milliQ water.  1µL of 
this lysate was transferred to a PCR tube with 12.5µL REDTaq® ReadyMix™, 5.5µL 
water, 0.5µL (0.5µM) forward primer, and 0.5µL reverse primer.  Primer sequences are: 
Stat3 forward 5’-ATT GGA ACC TGG GAC CAA GTG G-3’, Stat3 reverse 5’-ACA 
TGT ACT TAC AGG GTG TGT GC-3’, Cre forward 5’-GAG TGA TGA GGT TCG 
CAA GA-3’, Cre reverse 5’-CTA CAC CAG AGA CGG AAA TC-3’.  The PCR tubes 
were put in a PTC-11 Peltier Thermal Cycler for 39 cycles (1 min at 94°C, 30 sec at 94°C, 
30 sec at 55°C, and 30 sec at 68°C).  The tubes were then removed and loaded into a 2.5% 
agarose gel with 1x SYBR safe DNA stain.  A 100 bp ladder was used.  After 
electrophoresis, there are bands of three different sizes.  The STAT3 
flox/flox
 mice have 
two loxp sequences and produces a 520bp band.  STAT3
+/+
 mice lack the loxp sequences 
and therefore produce a smaller490bp band.  Cre mice produce a 615bp band if it is 
present (Figure 7).  STAT3
flox/flox
, Cre
+
 mice will be referred to as conditional knockout 
(KO) and STAT3
+/+
, Cre
+
 mice will be referred to as wild type (WT). 
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2.3 Immunohistochemistry 
 
Slides of paraffin-embedded mouse femur and tibia were deparaffinized using three 
changes of xylene for 5 minutes each and then rehydrated in graded ethanols.  The slides 
were transferred to phosphate buffered saline (PBS) for 5 minutes before being immersed 
in DeCal Epitope retrieval Solution for 30 minutes.  All slides spent two 5 minute 
sessions in methanol and two in PBS to rinse the DeCal solution.  Slides were transferred 
to a PBS+ 0.3% Triton X-100 solution for 10 minutes and stored in PBS until use.   
Next, a 3% H2O2/methanol solution was applied for 5 minutes and then rinsed 
twice with PBS.  A 1.5% goat serum blocking solution (VectaStain ABC kit) was applied 
to each slide for 30 minutes.  After rinsing in PBS, a STAT3 primary antibody solution 
was applied to each slide before storing overnight at 4°C. 
The following day, all primary antibody solution was rinsed from the slides using 
PBS before a biotinylated secondary antibody (VectaStain ABC kit) was applied to all 
slides with the exception of the negative control, which received 1.5% goat serum 
blocking solution for 45 minutes.   
After two rinses with PBS an avidin-conjugated peroxidase (ACP) solution was 
applied to the slides for 30 minutes.  The negative control received a 1.5% goat serum 
blocking solution.  Finally, the ACP solution was rinsed away with PBS and a peroxidase 
substrate solution was applied to all slides for 1 minute. 
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2.4 Bone Mineral Density (PIXImus) 
 
 Bone mineral density (BMD) and bone mineral content (BMC) were observed in 
femurs and lumbar vertebra 4 (L4) from 8 and 16 week old mice using a PIXImus 
densitometer.  Bones were placed in the center of the scanning tray.  BMD and BMC 
were calculated using the PIXImus program. 
 
2.5 Mechanical Testing 
 
The left femur from mice euthanized at 8 weeks old was extracted and stored in 
saline at -20°C prior to 3-point bending.  All femurs were loaded into a 500lb. actuator 
(Test Resources) with a 25 lb. loading cell.  The span of the bottom 2 contacts was set at 
6mm apart to accommodate all femurs while the top contact was placed midway between 
these points.  The midpoint of each femur was placed at the top contact.  Load was 
applied in a posterior-anterior direction by the top contact at 0.03mm per second until 
failure or 30N.  Force-displacement and stress-strain curves were generated during this 
time.  Break points were found by measuring from the distal end to the break point at the 
anterior face of each femur. [67] 
 
 
 
 
21 
 
2
1
 
2.6 Micro CT 
 
Left femurs were isolated from mice euthanized at 8 and 16 weeks old and stored in 
saline at -20°C.  Femurs were scanned using a Skyscan 1172 micro-CT scanner (Bruker-
microCT, Belgium).  All images were acquired with a 6.0µm pixel size.  Data were 
analyzed using the program CTan and 3D models were constructed using CTvol. 
 
2.7 Osteoclast Cell Culture 
 
Femur and tibia for both right and left legs were collected for each mouse.  Soft 
tissue was removed from the bones and the bones were placed in αMEM containing 10% 
FBS and antibiotics for transport.  Bones were then transferred in αMEM supplemented 
with 2% FCS and more soft tissue was removed.  After cleaning, the bones were moved 
to a petri dish containing 10% FCS in αMEM.  The epiphyses were cut from each bone 
and the marrow was flushed from the diaphyses into a centrifuge tube using a syringe and 
needle with 10% FCS in αMEM.  Cells were washed twice before use.  Cells were 
counted on a hemacytometer.   
Next, 0.2µL/mL M-CSF and 0.5µL/mL RANKL (R&D Systems) were added to 
each tube.  The cell suspension was then dispensed into the wells of a Corning 
Osteoassay culture plate (Corning Incorporated), starting with the smallest wells and 
working up to the larger ones.  The 96 well plate received 200µL/well (100,000 cells).  
1mL per well (500,000 cells) was dispensed into the 24 well plate and 2mL/well 
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(1,000,000 cells) was added to the 6 well plates.  The cells were fixed with 2.5% 
glutaraldehyde in phosphate buffered saline and stained for TRAP before counting. 
 
2.8 Histology 
 
Specimens were fixed in formalin for at least 24 hours and dehydrated using a 
series of ethanols before being cleared using xylenes.  All specimens were infiltrated 
using unpolymerized methyl methacrylate and unpolymerized methyl methacrylate with 
4% dibutyl phthalate.  Specimens were transferred to methyl methacrylate, 3% dibutyl 
phthalate, and 0.25 % Perkadox 16.  Polymerization occurred at room temperature. Thin 
sections of trabecular bone were cut 4-10 µm thick using a rotary microtome and 
mounted on microscope slides.  Thick sections of cortical bone were cut 100µm thick 
using a diamond-wire saw and sanded to a final thickness of 30µm before observation. 
 
2.8.1 Tartrate Resistant Acid Phosphatase (TRAP) Stain 
 
Sections were first deplastified in acetone and rehydrated using ethanols.  Slides 
containing the sections were then incubated in a pH 5.0 sodium acetate buffer containing 
0.2M sodium acetate and 50mM sodium tartrate dibasic dihydrate for 20 min.  Slides 
were then transferred to a pH 5.0 sodium acetate buffer containing 0.2M sodium acetate, 
50mM sodium tartrate dibasic dihydrate, 0.5mg/mL napthol AS-MX phosphate, and 1.1 
mg/mL fast red TR salt for 1 hour at 37°C.  Sections were then counterstained with 
hematoxylin. [68] 
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2.8.2 VKM Stain 
 
Sections were deplastified and rehydrated as above.  Slides were then stained in a 
5% silver nitrate solution, rinsed, and stained in a sodium carbonate-formaldehyde 
solution containing 5 % sodium carbonate and 25mL formaldehyde per 100mL.  Slides 
were then rinsed twice and transferred to Farmer’s diminisher for 20 seconds.  After 
washing, sections were stained in a 2% MacNeal’s tetrachrome solution for 20 min.  
Sections were rinsed 3 times, dehydrated in ethanol, and cleared using xylenes. [69] 
 
2.9 Histomorphometry 
 
All mice were injected with the fluorescent dyes calcein and alizarin.  Calcein was 
injected one week before sacrifice and alizarin was injected 2 days before sacrifice.  
Sections were observed using an Olympus BX53 light/fluorescent microscope and 
Olympus DP72 camera interfaced with Osteomeasure™ software version 
1.01(OsteoMetrics Inc, Decatur GA).  An area 0.4mm proximal from the growth plate 
and 0.5mm medial from cortical bone (approx. 1.4mm
2
 for labels and Trap stain, 
0.60mm
2
 was examined for VKM slides).  All measurements were taken at 200x for 
labels and Trap stain, 400x for VKM stain.  All measurements and abbreviations were 
made according to Parfitt et al. [70]  These abbreviations and formulas used can also be 
found in Tables 1 and 2.  Mice lacking one of the fluorescent labels were given a mineral 
appositional rate of 0.1µm/day to avoid leaving a MAR of zero and allow for calculation 
of bone formation rates. [71] 
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2.10 Statistics 
 
Data were reported as mean ± standard deviation.  Difference between group means 
was tested using a 2-sample t-test in Minitab (Minitab Inc. PA).  Statistical significance 
was assumed if P < 0.05. 
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CHAPTER 3. RESULTS 
 
3.1 Verification of Osteoclast Specific Knockout Mice  
 
Mice were generated as described previously described.  An immunohistochemical 
stain was performed to verify the knockout of STAT3 in osteoclasts.  The expression of 
STAT3 was shown to be decreased in osteoclast specific STAT3 KO mice (Figure 9). 
 
3.2 Comparison of Mouse Body Weight and Femur Length 
 
There were no significant differences in mouse body weight (Figure 10) or femur 
length (Figure 11) among TRAP-Cre or CTSK-Cre mice.  Both males and females were 
similar at age 8 weeks and 16 weeks.  Unless otherwise noted, data was collected for 12 
WT female and male mice and for 17 cKO females and males. 
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3.3 CTSK Specific Knockout Female Mice Decrease in BMD 
 
At 8 weeks, CTSK specific Stat3 knockout female mice demonstrated an 8.6 % 
significant decrease in BMD (p < 0.05) and a 13.6% decrease in BMC (p < 0.05) of the 
left femur compared to control (Figure 12).  BMD values were 0.0431±0.003g/cm
2
 for 
female WT and 0.0394 ±0.003 for g/cm
2
 for female cKO mice.  WT female BMC was 
0.0162±0.003g and cKO was 0.014±0.002g.  Males showed a non-significant 1.1% 
decrease in BMD (WT 0.0463±0.004g/cm
2
, cKO 0.0458±0.007 g/cm
2
) and a 3.7% 
decrease in BMC in Stat3 KO mice compared to their littermate controls (WT 
0.0188±0.002g, cKO 0.0181±0.004g).  However, at 16 weeks the BMD and BMC of 
Stat3 knockout females decreased 2.0% and 4.8% respectively (BMD: WT- 
0.0494±0.002 g/cm
2
 cKO-0.0485±0.004 g/cm
2
;  BMC WT-0.0208±0.001g cKO-
0.0208±0.003g) which was not a significant difference.  Neither BMD nor BMC changed 
in the 16 week old CTSK specific Stat3 knockout males as compared to littermate 
controls (Figure 13).  The TRAP specific Stat3 KO mice demonstrated no changes in 
BMD or BMC in the males or females that were 8 weeks of age (Figure 14). 
 
3.4 CTSK Specific KO Mice Trabecular Bone at 8 Weeks Old 
 
CTSK specific Stat3 KO mice had significantly decreased trabecular bone volume 
and trabecular number at 8 weeks of age in males and females.  Trabecular separation 
was significantly increased in CTSK specific STAT3 KO mice compared to controls 
(Figure 15).  Bone volume/tissue volume (BV/TV) was significantly (42%) in CTSK 
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specific Stat3 KO females compared to controls, while males displayed a significant 25% 
decrease in BV/TV.  Specifically, female WT BV/TV was 9.26±2.3%  and cKO BV/TV 
was 5.37±1.3%, while male WT BV/TV was 14.85±3.8% and cKO was 11.13±3.5%).  
Trabecular separation showed significant increases of 22% and 23% among CTSK 
specific Stat3 KO females and males, respectively.  Trabecular number significantly 
decreased 40% in female Stat3 KO mice (WT- 0.0745±0.0166/µm and cKO-
0.045±0.013/µm) and 31% in males.  These differences can be observed in the 3 
dimensional models in Figure 15.  On the other hand, no significant differences were 
detected between the 8 week old TRAP specific Stat3 KO and control with respect to 
BV/TV, trabecular thickness, trabecular number, or separation.  
 
3.5 CTSK Specific KO Mice Trabecular Bone 16 Week of Age 
 
At 16 weeks of age, the CTSK specific Stat3 KO mice had significantly higher 
trabecular bone than did controls (Figure 16).  Specifically, BV/TV increased 46% 
among the female Stat3 KO mice compared to controls while BV/TV increased 13% in 
males.  The trabecular number was also significantly higher in Stat3 KO compared to 
controls (45% in females and 13% in males).  Trabecular separation was significantly 
elevated in Stat3 KO females (18%), but a 5% increase was observed in male Stat3 KO 
mice compared to controls.  There were no significant differences detected in trabecular 
thickness among males or females.  
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3.6 CTSK Specific KO Increases the Number of Osteoclasts 
 
Data gathered from a TRAP stain of the distal femur revealed a significant decrease 
in osteoclast number among CTSK specific Stat3 KO mice compared to controls (Figure 
17).  The osteoclast number was significantly reduced 36% in female CTSK specific 
Stat3 KO (WT-71±23, cKO 45.6±32) and was reduced 9% (not statistically significant) 
in CTSK specific Stat3 KO males (WT-71.7±23, cKO- 64.8±24) compared to age and 
gender matched controls.  Although the trend for a reduction in the male KO mice, the 
standard deviation values were too high to detect a significant difference.  Calculation of 
osteoclast number/tissue area reveals similar results.  The osteoclast surface/bone surface 
was significantly lower (50%) in female CTSK specific Stat3 KO mice compared to 
controls (WT-1.24±0.5mm, cKO-0.63±0.4mm).  The TRAP specific cKO mice had a 41% 
decrease in osteoclast number/bone surface in females (WT-10.9±1.6/mm, cKO 
6.3±2.7/mm) and a 30 % reduction in males (WT-9.4±2.16/mm, cKO-6.5±2.04/mm) (see 
Figure 18). 
 
3.7 CTSK Specific STAT3 KO Trabecular BFR at 8 Weeks Old 
 
Analysis of calcein and alizarin labeled bone surfaces showed that the bone 
formation rate of CTSK specific Stat3 KO females was significantly lower (28%) than 
that observed in WT controls (WT-356±54 µm
3
/µm
2
/year, cKO 256±163 µm
3
/µm
2
/year 
(Figure 19).  The mineralizing surface/bone surface was also significantly decreased by 
20% in Stat3 KO females compared to WT controls (WT-42.0±7.69%, cKO-
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33.6±9.80%).  The Stat3 KO males displayed a 14% increase in mineral apposion rate 
and a 5% decrease in mineralizing surface/bone surface; however, the standard deviation 
on these values was too high to detect a significant difference likely owing to the fact that 
a few mice had only one fluorescent label present.  No significant differences were 
detected with respect to osteoblast number or osteoid surface. 
 
3.8 Cortical Bone Size and Growth Rate in STAT3 KO Mice 
 
Average cross-sectional bone area and cortical thickness were found not to be 
different in cortical bone at the midshaft in both 8 and 16 week old mice.  Analysis of the 
labeled femur midshaft showed that there are minimal decreases in periosteal MS/BS of 
STAT KO females and endocortical MAR in Stat3 KO males at age 8 weeks (Figure 21).  
No differences were found in cortical bone area or growth rates of TRAP specific STAT3 
KO mice. 
 
3.9 Mechanical Testing: 3 Point Bending 
 
Femurs from 8 week old CTSK specific Stat3 KO and wild-type mice were 
subjected to 3 point bending to determine their strength.  As shown in Figure 22, 
although not significantly different, the female Stat3 KO femurs had a 20% decrease in 
total toughness (WT-20.2±4.94MJ/m
3
, cKO-16.1±5.53 MJ/m
3
).  Similarly, although not 
statistically significant, Stat3 KO male femurs had a 19% increase in stiffness (WT-
58.0±9.51N/mm, cKO-71.8±20.6N/mm).  The ultimate force required to break the femur 
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increased by 13% in Stat3 KO males compared to their WT controls (WT-12.4N±1.7, 
cKO-14.3±3.1N).  Of note, total work was significantly decreased 23% in Stat3 KO 
female femurs compared to WT controls (WT-11.2±2.7mJ, cKO-8.63±2.7mJ.  All other 
measurements were similar. 
  
3.10 Osteoclast Cell Culture 
 
Osteoclasts were cultured from 6 week old female CTSK specific STAT3 KO and 
WT mice.  There was no significant difference detected in osteoclast number (Figure 23).  
Resorption area decreased in STAT3 KO mouse cultures compared to WT, although the 
difference was not statistically significant.  Two mice were gathered for each group.  
Triplicate wells were prepared from each mouse and two mice were utilized from each 
group (CTSK specific STAT3 KO and WT controls). 
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CHAPTER 4. DISCUSSION 
 
4.1 Decreased Osteoclast Number in STAT3 KO 
 
Recent studies have tied STAT3 to the osteoclast.  STAT3 has been shown to be 
involved in RANKL mediated osteoclast differentiation.  A study by Li et al. used the 
JAK2 inhibitor AG490 and found that osteoclast differentiation was decreased without 
JAK-STAT signaling. [66]  An experiment using siRNA was also performed to 
knockdown STAT3.  They found that some RANKL induced genes were downregulated 
and others were not. This shows that STAT3 is important for osteoclastogenesis but it is 
not the only transcription factor required for RANKL mediated osteoclastogenesis. [66] 
 
4.2 Osteoclast Number and BV/TV in Trabecular Bone 
  
 The decreased osteoclast number and trabecular bone volume in 8 week old mice 
suggests communication from the osteoclast to the osteoblast (Figure 15 and 17).  While 
no major differences were observed in bone formation rates on the fluorescent- labeled 
distal femur or from the osteoblast cell count, the osteoclast is known to have some 
influences on osteoblast activity.   
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 Osteoblast-osteoclast communication through RANKL and OPG is much better 
understood than osteoclast-osteoblast communication.  Candidates for osteoclast-
osteoblast communication include platelet derived growth factor, EphB4-EphrinB2 
interactions, and even osteoclast precursors.  Ephrin signaling through Eph can cause 
both osteoblast production and inhibition of osteoclastogenesis depending on the 
direction of signal.  Ephrin B2 binding EphB4 leads to increased osteoblast 
differentiation, while EphB4 binding to Ephrin B2causes a decrease in osteoclastogenesis. 
[72]   Immune system cells have also been tied to signaling the osteoblast.  Monocytes 
have been shown to bring an increase in osteoblast differentiation.  This study also found 
that STAT3 signaling was responsible for osteoblast differentiation, highlighting the role 
of STAT3 in osteoblasts as well as osteoclasts. [73] 
 
4.3 Differences in Bone Phenotypes at age 8 and 16 Weeks 
 
The phenotypes of CTSK specific STAT3 KO mice reversed between the ages of 8 
and 16 weeks.  In the 8 week old mice, trabecular bone volume and number was 
decreased among STAT3 KO (Figure 15).  In the 16 week old group, the STAT3 KO 
mice had a larger trabecular bone volume and number (Figure 16).  Although the 
difference observed in bone phenotype between 8 week old and 16 week old mice may 
suggest changes with aging/development, caution must be taken in this interpolation as 
different control mice were used in the 8 week vs. 16 week studies.   
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Specifically, each genotype of the control mice in the 8 week old study was 
STAT3
+/+
 Cre+, while the genotype of the 16 week old control mice was STAT3
flox/flox
 
Cre-.  The latter mice came from a previous study.   
Some of our findings also implicate gender-based differences.  For example, female 
CTSK specific STAT3 KO mice had larger decreases in osteoclast number and trabecular 
bone volume than did the males.  This suggests sex hormones, such as estrogen, may 
have influences on bone through STAT3. 
 
4.4 Males Exhibit Stronger Cortical Bone In STAT3 KO 
  
As seen in Figure 22, although not significantly different from controls, the CTSK 
specific STAT3 KO males displayed similar or elevated bone mechanical parameters 
compared to their wild-type controls without any differences in cortical thickness or bone 
area at 8 weeks of age.  These observations are of interest as the female CTSK specific 
STAT3 KO femurs had reduced biomechanical properties with total work being 
significantly reduced compared to WT female femurs.  This suggests that STAT3 may 
also have a gender-based effect on the quality of bone matrix. 
 
4.5 Future Plans 
 
Future plans for this experiment include looking into the mechanism by which 
STAT3 decreased osteoclast number and trabecular bone parameters.  Observing 
histological slides for the 16 week old CTSK and TRAP specific STAT3 KO mice would 
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be beneficial.  Mechanical testing of these same groups should also be done.  Generating 
16 week old CTSK control mice with the same genotype used as a control in all other 
experiments will also be done to confirm findings. 
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Table 1 Abbreviations and formulas for parameters used in cortical bone 
 
parameter abbreviation units formula 
cortical bone area Ct.B.Ar mm2  
cortical tissue area Ct.T.Ar mm2  
cortical marrow area Ct.Ma.Ar mm2  
bone volume/tissue volume Ct.BV/TV % Ct.B.Ar/Ct.T.Ar 
cortical thickness Ct.Th um  
periosteal perimeter Ps.Pm mm  
periosteal inter-label thickness Ps.Ir.L.Th um  
periosteal single-label surface/bone surface Ps.sL.S/BS %  
periosteal double-label surface/bone surface Ps.dL.S/BS %  
periosteal mineralizing surface/bone surface Ps.MS/BS % Ps.(dL.Pm+sL.Pm/2)Ps.B.Pm 
periosteal mineral apposition rate Ps.MAR um/d Ps.Ir.L.Th/time between labeling 
periosteal bone formation rate/bone surface Ps.BFR/BS um3/um2/y Ps.MAR*(Ps.MS/BS)*365 
periosteal bone formation rate/bone volume Ps.BFR/BV %/y Ps.MAR*(Ps.(dL.Pm+sL.Pm/2)/Ct.B.Ar)*365 
periosteal bone formation rate/tissue volume Ps.BFR/TV %/y Ps.MAR*(Ps.(dL.Pm+sL.Pm/2)/Ct.T.Ar)*365 
endocortical perimeter Ec.Pm mm  
endocortical inter-label thickness Ec.Ir.L.Th um  
endocortical single-label surface/bone surface Ec.sL.S/BS %  
endocortical double-label surface/bone surface Ec.dL.S/BS %  
endocortical mineralizing surface/bone surface Ec.MS/BS % Ec.(dL.Pm+sL.Pm/2)Ec.B.Pm 
endocortical mineral apposition rate Ec.MAR um/d Ec.Ir.L.Th/time between labeling 
endocortical bone formation rate/bone surface Ec.BFR/BS um3/um2/y Ec.MAR*(Ec.MS/BS) 
endocortical bone formation rate/bone volume Ec.BFR/BV %/y Ec.MAR*(Ec.(dL.Pm+sL.Pm/2)/Ct.B.Ar)*365 
endocortical bone formation rate/tissue 
volume 
Ec.BFR/TV %/y Ec.MAR*(Ec.(dL.Pm+sL.Pm/2)/Ct.T.Ar)*365 
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Table 2 Abbreviations and formulas for parameters used in trabecular bone 
parameter abbreviation units formula 
tissue area T.Ar mm2  
bone area B.Ar mm2  
bone perimeter B.Pm mm  
double-label perimeter dL.Pm mm  
single-label perimeter sL.Pm mm  
inter-label thickness Ir.L.Th um  
mineralizing surface/bone surface MS/BS % (dLPm+sLPm/2)B.Pm 
mineral apposition rate MAR um/day Ir.L.Th/time between labeling 
bone formation rate/bone surface BFR/BS um3/um2/y MAR*(MS/BS) 
bone formation rate/bone volume BFR/BV %/y MAR*((dL.Pm+sL.Pm/2)/B.Ar)*365 
bone formation rate/tissue volume BFR/TV %/y MAR*((dL.Pm+sL.Pm/2)/T.Ar)*365 
bone volume/tissue volume BV/TV % B.Ar/T.Ar 
osteoclast perimeter Oc.Pm mm  
number of osteoclasts N.Oc #  
osteoclast surface/bone surface Oc.S/BS % Oc.Pm/B.Pm 
number of osteoclasts/tissue area N.Oc/T.Ar #/mm2 N.Oc./T.Ar 
number of osteoclasts/bone perimeter N.Oc/B.Pm #/mm N.Oc/B.Pm 
number of osteoclasts/osteoclast perimeter N.Oc/Oc.Pm #/mm N.Oc/Oc.Pm 
osteiod area O.Ar mm2  
osteoblast perimeter Ob.Pm mm  
number of osteoblasts N.Ob #  
osteiod volume/tissue volume OV/TV % O.Ar/T.Ar 
osteoid volume/bone volume OV/BV % O.Ar/B.Ar 
osteoid surface/bone surface OS/BS % O.Ar/B.Pm 
osteoblast surface/bone surface Ob.S/BS % Ob.S/B.Pm 
number of osteoblasts/bone perimeter N.Ob/B.Pm #/mm N.Ob/B.Pm 
number of osteoblasts/osteoblast perimeter N.Ob/Ob.Pm #/mm N.Ob/Ob.Pm 
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Figure 1:  Osteons.  Osteons of trabecular bone (left) and cortical bone (right)  [1] 
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Figure 2: Bone remodeling units.  Bone remodeling units for trabecular bone (top) and 
cortical bone (bottom) [1] 
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Figure 3: Stress-stain curve (left) and force-displacement curve (right) 
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Figure 4:  STAT3 activation.  STAT3 is activated through the JAK-STAT signaling 
pathway along with other starting points [58] 
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Figure 5:  STAT3 crystalline structure [50] 
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Figure 6:  Membrane receptors for IL-6 family cytokines [46] 
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Figure 7:  Determination of mouse genotype.  The smaller 490bp belongs to the 
STAT3
+/+
 (wilt type) mice while the 520bp fragments contain loxp sites.  The 615 bp 
band represents Cre. 
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Figure 8:  Mechanical testing: bone loaded into position for three point bending 
(top) and actuator (bottom) 
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Figure 9:  Immunohistochemical staining.   Decalcified mouse femurs were stained using 
an anti-phosphorylated STAT3 primary antibody;  A is a wild-type mouse while B is an 8 
week old CTSK specific STAT3 KO.  The arrow is pointing to a phospho-STAT3 
positive osteoclast
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Figure 10:  Body weights of osteoclast specific Stat3 mice at age 8 and 16 weeks 
(A=CTSK 8 week, B=CTSK 16 week, C=TRAP 8 week).  No significant differences 
were detected 
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A)  
 
B)  
 
C)  
Figure 11:  Femur length of osteoclast specific STAT3 KO mice at age 8 and 16 weeks 
(A= CTSK 8 weeks, B=CTSK 16 weeks, C=TRAP Femur 8 weeks).  No differences 
were detected. 
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Figure 12:  BMD and BMC of 8 week CTSK STAT3 KO mice.  Bone mineral density (A) 
and bone mineral content (B) of CTSK STAT3 KO mice.  Left femurs were collected 
from mice at 8 weeks of age and scanned using a PIXImus scanner.  Bone mineral 
density and bone mineral content were decreased in female cKO mice compared to 
female WT mice (*:  p<0.05) 
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Figure 13:  BMD and BMC of adult CTSK mice.  Bone mineral density (A) and bone 
mineral content (B) of femurs from adult CTSK mice.  Left femurs were collected from 
mice at 16 weeks of age and scanned using a PIXImus scanner.  No significant 
differences were detected. 
 
 
  
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
Female WT Female cKO Male WT Male cKO
B
M
D
 (
g/
cm
2  
) 
CTSK Bone Mineral Density 16 Week 
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
Female WT Female cKO Male WT Male cKO
B
M
C
 (
g)
 
CTSK Bone Mineral Content 16 Week 
55 
 
5
5
 
A)  
 
B)  
 
Figure 14:   BMD and BMC of 8 week old TRAP STAT3 KO mice.  Bone mineral 
density (top) and bone mineral content (bottom) of femurs from 8 week old TRAP 
STAT3 KO mice.  Left femurs were collected from mice and scanned using a PIXImus 
scanner.  No significant differences were detected. 
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A)  
B)  
    
    
Figure 15:  Trabecular bone structure of 8 week old CTSK mice.  Three dimensional 
models of a 0.5mm thick trabecular bone area 1mm proximal from growth plate (A) and 
graphs depicting data gathered from the same area (B)  Data were collected from 
microCT scan of left femurs.  Trabecular number and Bone volume/tissue volume 
significantly increased in cKO males and females compared to age and gender matched 
controls, while trabecular separation was significantly lower in cKO female mice 
compared to WT females (*: p < 0.05). 
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Figure 16:  Trabecular bone structure of 16 week old CTSK mice.  Three dimensional 
models of a 1mm thick trabecular bone area 1mm proximal from growth plate (A) and 
graphs depicting data gathered from the same area (B) Data were collected from microCT 
scan of left femurs.  Trabecular number and bone volume/tissue volume both increased (*: 
p<0.05) 
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Figure 17:  TRAP stain CTSK specific STAT3 KO mice.  TRAP stain of female distal 
femur (A) and graphical representation of data (B) Data was collected from a region 
0.8mm proximal from the growth plate of the right femur.  Osteoclast number and 
osteoclast number/tissue area decreased in cKO females (*: p<0.05)  
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A)  
B)  
 
Figure 18:  TRAP stain TRAP specific STAT3 KO mice.  TRAP stain of right femur 
from 8 week old TRAP specific STAT3 KO mice.  Data was collected from a region 
0.8mm proximal from the growth plate of the right femur.  Osteoclast number and 
osteoclast number/tissue area decreased significantly in cKO females compared to 
controls (*: p<0.05)  
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Figure 19:  Dynamic histomorphometry CTSK mice.  Dynamic histomorphometry from 
the distal femur of female CTSK STAT3 WT (left) and KO (right) mice (A) and 
graphical representation of data.  Data were collected from a region 0.8mm proximal 
from the growth plate of the right femur.  Calcein and alizarin dyes were injected into the 
mouse 5 days apart. Bone formation rate and mineralizing surface/bone surface were 
decreased in cKO females compared to WT females (* p<0.05) 
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Figure 20:  Dynamic histomorphometry TRAP mice.  Quantitated data from fluorescent-
labeled trabecular bone from right femur of 8 week old TRAP STAT3 WT and cKO mice.  
Data was collected from a region 0.8mm proximal from the growth plate of the right 
femur.  Calcein and alizarin dyes were injected into the mouse 5 days apart.  NO 
significant differences were detected. 
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Figure 21:  Cortical bone properties 8 week old CTSK STAT3 mice (A)  Cortical bone 
micro CT images from the exact midpoint of the left femur. B) graph of bone area and C) 
Periosteal MS/BS and endocortical MAR  Calcein and alizarin dyes were injected into 
the mouse 5 days apart.  NO significant differences were detected. 
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Figure 22:  Mechanical testing of CTSK mouse femur.  Femurs from 8wk old CTSK 
STAT3 KO and WT mice were subjected to 3 point bending to determine strength.  Left 
femurs were arranged with anterior side facing downward and loaded with bottom points 
set 6mm apart with top bending point set in center.  A significant difference was detected 
between WT and cKO female mice in total work (*: p<0.05). 
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Figure 23:  Osteoclast cell culture data.  Bone marrow cells were isolated from 6 week 
old CTSK STAT3 KO and WT mice and were cultured in the presence of RANKL and 
M-CSF and the number of mature osteoclasts formed as well as the percent of resorbed 
area was assessed.  A) TRAP stained osteoclasts in WT and KO cultures,  resorption pit 
assay B) resorbed surface appears darker than unresorbed surface of osteoassay tissue 
culture plates, C) qunatitation of the resorption area.  N=2 mice pre group.  No significant 
differences were found. 
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